Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Msci Inc (MSCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Msci Inc vs Neurocrine Biosciences Inc — how do they compare? Msci Inc trades at $560.08 (market cap $40.84B), while Neurocrine Biosciences Inc trades at $157.4 (market cap $16.46B). The key difference: Msci Inc is far larger — about 2.5× Neurocrine Biosciences Inc's market cap, and Msci Inc pays a 1.46% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

MSCINBIX
Market Cap
$40.84B$16.46B
Sector
FinancialsHealth
52-Week High
$643.83$185.50
52-Week Low
$511.84$123.10
Enterprise Value
$47.00B$16.48B
Dividend Yield
1.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Msci Inc

MSCI trades at $562.00, down 0.19% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The company reported Q2 2026 EPS of $4.94, slightly missing the $4.99 estimate, yet revenue growth remains robust, with 2025 revenue at $3.13 billion and net income margin of 40.73%. Recent acquisitions like First Street and partnerships with UBS aim to expand its private markets analytics platform, supporting long-term growth.

Outlook is positive with a consensus price target of $728.14, implying 30% upside, driven by strong recurring revenue and high client retention. Risks include elevated debt levels of $4.51 billion and competitive pressures in financial data services. Analysts maintain 73% buy ratings, citing undervaluation relative to growth prospects, but investors should monitor execution on integration of recent acquisitions and interest rate impacts on financing costs.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX